GlaxoSmithKline and Kymera have sealed a pact to work together on the discovery of new medicines based on protein degradation.
The parties have entered a two-year discovery collaboration that will see them work together work together on a limited number of protein degradation targets “of mutual interest”, with the help of the US biotech’s proprietary Pegasus drug discovery platform.
Targeted protein degradation redirects the body’s innate protein degradation and recycling system to degrade disease-causing proteins.
The companies will also collaborate on the discovery of novel E3 ligases – the enzymes that bind and target disease-causing proteins marking them for degradation.
Each firm has the right to use certain insights gained in the collaboration for its own programmes.
Financial details were not disclosed.
